演題詳細

一般口演 / Oral Session

【E】一般口演 21 (Oral Session 21) :Hematopoietic Cell Transplantation

print

日程
2013年10月11日(金)
時間
14:25 - 15:25
会場
第5会場 / Room No.5 (さっぽろ芸文館 3F 清流)
座長・司会
石山 謙 (Ken Ishiyama):1
1:Div. Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
 
前へ戻る

Hematopoietic cell transplantation depending on the donor differences in adult acute lymphoblastic leukemia

演題番号 : OS-1-108

Dae-Young Kim (金 大英):1、Han-Seung Park:1、Je-Hwan Lee:1、Jung-Hee Lee:1、Hye Jeong Park:1、Seunghyun Baek:1、Mijin Jeon:1、Young-Shin Lee:1、Young-Ah Kang:1、Miee Seol:1、Yeon-Joo Lee:1、Kyoo-Hyung Lee:1

1:Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

 

We evaluate the feasibility of allogeneic hematopoietic cell transplantation (alloHCT) using haploidentical familial donor (HFD) in adult acute lymphoblastic leukemia (ALL). Patients over 16 years old with ALL were enrolled in this prospective trial in Asan Medical Center, if he/she was in first (CR1) or second (CR2) complete remission and agreed with alloHCT as PRT. Those who had a matched sibling donor (MSD) received stem cell from bone marrow (BM) or peripheral blood (PB) with conventional (CON) conditioning (age<55) consisting of busulfan plus cyclophosphamide or nonmyeloablative (NMA) one (age≥55) consisting of fludarabine, busulfan, and thymoglobulin. When MSD was unavailable, PB stem cell from unrelated donor (UD) with full-match or acceptable mismatch and HFD was considered in sequence with NMA conditioning irrespective of the age of patient. Fifty patients who received alloHCT from Jan 2010 until Aug 2012 were included in this interim analysis. Donor groups were MSD (n=13) / MUD (n=20) / HFD (n=17), and BM (n=12) / PB (n=38) was adopted as stem cell source. Eleven patients received CON and the other ones received NMA as a conditioning. Distribution of immunophenotype, Ph status, and risk group was not significantly different between donor groups, except the proportion of advanced status was higher in HFD group (35%; REL[5], CR2[1]). Among 42 patients in CR1/CR2 at the initiation of conditioning, 2-year RFS rate (78.0% as a whole) was likely to be higher in HFD group than non-HFD (MSD+UD) group (83.3% vs. 68.4%, p=0.615). Among all patients including those in REL, 2-year OS rate (57.3% as a whole) was nearly in statistical significance (59.5% vs. 58.7%, p=0.053). In this study, AlloHCT strategy considering HFD as third-party stem cell source was feasible and the outcome was satisfactory as post-remission therapy in adult ALL.

前へ戻る